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SUMMARY 
• Peptide tyrosine-tyrosine (PYY) and neuropeptide tyrosine 
(NPY) are emerging as potent central nervous system 
regulators of digestive functions. There is, however, 
considerable debate concerning the mechanisms and even 
the direction of autonomic effects mediated by these pep-
tides. PYY is thought to be the hormonal "enterogastrone" 
released by the ileum after feeding. This peptide acts on 
vagal reflex control circuits in the dorsal vagal complex 
(DVC) of the medulla oblongata to reduce gastric motility, 
i.e. the "Heal brake". However, equally convincing evidence 
is available to suggest that PYY and its close structural 
relative NPY may also act in the DVC to increase gastric 
motility through vagal mechanisms. This activation effect, 
particularly of NPY, has been linked to the increase in 
digestive functions seen at the onset of feeding behaviour, i.e. 
Pavlov's "cephalic phase". We hypothesize that the 
confounding observations produced by these peptides are 
due to agonist effects on two different receptor types referred 
to as Yl and Y2. Both receptors are present in the DVC but 
may be accessed differentially by peripheral humoral (PYY) 
versus central neurotransmitter (NPY) pathways. Our 
experiments show that the hormonal effect of PYY to suppress 
gastric functions such as the "Heal brake" is consistent with 
the activation of the Y2 receptor in the DVC, 
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while NPY-ergic effects to increase gastric functions are 
mediated by the Yl receptor. These results are 
corroborated by neurophysiological studies of the effects 
ofYl and Y2 agonist peptides on single vagal efferent 
neurons. The seemingly paradoxical effects of PYY and NPY 
on the central neural control of gastric motility are reviewed 
in terms of the possible differential localization of Yl 
versus Y2 receptors within the DVC. Specific reference is 
also made to recent observations that PYY is rapidly 
converted to a Y2 agonist by an ubiquitous dipeptidyl 
aminopeptidase. (Biomed Rev 1997; 8: 55-69) 
INTRODUCTION 
• PYY and NPY were originally extracted and purified from 
porcine small intestine and brain, respectively (1-5). Both 
contain 36 amino acids, show a 70% sequence homology and 
display a high degree of three dimensional structural 
conservation (3, 5). PYY-releasing endocrine cells are 
located mainly in the mucosa of the terminal ileum and colon (4- 
See Editorial Comment on page 70  
In contrast, NPY is one of the most abundant peptides found 
in neurons in the brain. It is concentrated in neural pathways 
associated with the control of feeding behaviour, endocrine 
and autonomic functions. Its synthesis and release are strongly 
associated with physiological conditions leading to increased 
food intake such as growth, pregnancy, and starvation. NPY 
injections into hypothalamic and brainstem structures 




elevations in feeding (11-15). 
PYY EFFECTS ON DIGESTIVE PROCESSES 
• Following a meal, PYY levels in plasma are increased 
significantly and remain elevated for several hours (4, 5). 
Circulating PYY concentrations can also be specifically 
elevated in response to direct infusion of oleate into the ileum 
(5, 6, 10). PYY produces inhibitory effects on digestive 
functions, gastric acid output, motility, and emptying as well 
as reduction of stimulated pancreatic exocrine secretion, and a 
prolongation of intestinal transit time (4, 5, 7, 8, 16-18). All of 
these effects are dependent upon intact vagal connections 
between the brainstem and the digestive tract (5). 
DORSAL VAGAL COMPLEX: CENTRAL NERVOUS 
SYSTEM TARGET FOR THE HORMONAL ACTION OF 
PYY 
• The dorsal vagal complex of the medulla oblongata (DVC) 
contains the basic neuronal circuitry for the reflex vagal 
control of digestion, often termed the vago-vagal reflexes. 
Vago-vagal reflex control is mediated by general visceral 
afferent fibers in the vagus nerve which carry a wide variety of 
sensory information from the gut. These vagal afferent fibers 
synapse in the nucleus of the solitary tract (NST). This 
nucleus maintains connections with vagal motorneurons in the 
dorsal motor nucleus of the vagus (DMN), which are the source 
of virtually all parasympathetic innerva-tion of the 
subdiaphragmatic viscera (19). The NST is also the source of 
input to interneurons in the reticular formation which control, 
by descending pathways, sympathetic efferent activity in 
preganglionic neurons of the intermediolateral cell column 
(20). Additionally, the NST is the principal source of ascending 
visceral afferent information used by other central nervous 
system (CNS) structures to monitor a wide variety of 
physiological parameters including, but certainly not limited 
to, the progress of digestion of a meal. 
Several categories of vago-vagal reflexes have been 
identified. The simplest such reflex is the gastric 
accommodation reflex, which utilizes mucosal contact 
receptors in the antrum to control the parasympathetic "tone" 
of the proximal stomach, and the rate of delivery of chyme to 
the duodenum. Evidence suggests that this is a simple 
disynaptic reflex whereby activation of vagal afferents 
activates NST neurons which, in turn, inhibit excitatory 
cholinergic neurons in the DMN (21,22). Other vago-vagal 
reflex "types" may be much more complicated. The gastric 
receptive relaxation reflex which is elicited by the activation 
of esophageal distension sensors during swallowing serves as 
an example. This reflex may involve the simultaneous and 
coordinated inhibition of DMN neurons controlling 
cholinergic excitation of the stomach and excitation of DMN 
neurons controlling the 
 
inhibitory non-adrenergic, non-cholinergic (NANC) enteric 
inputs to gastric smooth muscle (23). The -end result is the 
relaxation of the proximal stomach to accept ingesta. 
Evidence has accumulated over the last few years which 
suggests that this brainstem region, which contains the digestive 
tract reflex control circuits, i.e. the DVC, may be outside the 
confines of the "blood-brain barrier" (24-26). Therefore, vago-
vagal reflex circuitry in the brainstem may also be under 
"humoral afferent control" (20). The best example for such 
"endoneurocrine" regulation of autonomic functions may be 
found in the explanation of the gastroinhibitory effects of 
PYY. 
Saturable and specific binding of circulating PYY to sites in 
the DVC has been demonstrated (26). This suggests that 
circulating PYY is capable of exerting direct feedback control 
ove* th/e progress of digestion by actmg OTI vago-vagal reflex, 
control circuitry. Our earlier physiological studies showed 
that microinjection of low doses (4-400 fmol in 20 nL) of 
PYY into the DVC could produce a vagally-mediated suppression 
of stimulated gastric motility (27). On the basis of this 
evidence, we suggested that PYY could be responsible for an 
"ileal brake" effect on gastric motility. In other words, ileal 
filling induces a negative feedback suppression of further 
gastric transit via PYY release. Circulating PYY then acts 
directly on vagal regulatory circuits in the brainstem to control 
gastric function (20). However, relatively higher doses of PYY 
(greater than 4 pmol in 20 nL) applied to the same brainstem 
area, i.e. the DVC, can also strongly activate gastric functions 
(27, 28). This dichotomy of CNS effects is also elicited by 
NPY. Thus, many reports link the release of NPY with the 
augmentation of motility (and other gastrointestinal functions) 
during the "cephalic phase" of digestion associated with food 
intake (29-32). Others, however, find that NPY injected 
centrally reduces digestive functions possibly via action on 
the same circuitry (33-35). One explanation for the apparent 
paradoxical experimental effects of NPY and PYY may have 
to do with the existence of multiple receptor populations for 
these peptides which overlap in the DVC. 
Binding sites for both PYY and NPY have been identified in 
the peripheral tissues and in the CNS. For example, PYY 
receptors have been found along the gastrointestinal tract as 
well as pancreas, spleen, kidney tubules, and several neuroen-
docrine cell lines (1, 36-41). In the brain, NPY and PYY 
binding sites are seen in a variety of areas, including cortex, 
hypothalamus, pons and, especially, the medulla oblongata 
(11, 15, 23). Results from binding studies have characterized at 
least five distinct subtypes of receptors for NPY and PYY, 
denoted Yl through Y5. Two of these receptors subtypes, Yl 
and Y2, are both found in large quantities in the dorsal vagal 
complex of the medulla. Both Y1 and Y2 receptors bind PYY 
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and NPY with high affinity (42). The Y2 subtype can be 
activated by C-terminal fragments of PYY and NPY, while the Yl 
subtype requires a full sequence of either polypeptide (13, 42). 
The DVC area containing Yl and Y2 receptors receives an 
especially dense NPYergic terminal innervation (11, 43). 
Additionally, a specific receptor for the structurally similar 
pancreatic polypeptide (PP) has been described (13, 15, 44-
47). Therefore, the overlapping distribution of Yl and Y2 
receptors in the DVC may explain some of the confusion 
concerning the physiological role of PYY and NPY to modulate 
vago-vagal reflex control of gastric motility. To test this idea, 
we investigated the effects of PYY, NPY, Yl, and Y2 
agonists on gastric motility (measured by strain gauges) when 
microinjected directly into the DVC under conditions of 
either maximal central vagal stimulation of motility or in the 
basal, unstimulated state (12, 48, 49). 
DVC ACTIONS OF PYY, NPY AND ANALOGS 
• PYY is normally released following feeding behaviour when 
gastrointestinal motility is elevated (4-6,10). To model this 
motility state in the anesthetized rat, the peptide thyrotro-pin 
releasing hormone (TRH) is microinjected onto the DVC. This 
peptide, which is normally released from terminal endings of 
the raphe nuclei in the brainstem onto neurons of the DMN, 
promotes a specific excitation of parasympathetic vagal 
projections to the stomach thus mimicking the increase in 
gastric motility following feeding (20, 50-52). 
Microinjection of the Y2 agonist (PYY 13-36) into the DVC 
(20 nL containing graded concentrations of the agonist pep-
tides) causes a dose-dependent inhibition of TRH-stimulated 
antral motility as previously seen (27) after microinjection of 
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Figure 1. Effects of different doses of PYY, NPY, Yl, and Y2 agonists microinjected into the dorsal vagal complex on TRH-
stimulated gastric motility. Data are depicted as means, +/- standard error. Statistical comparisons made at the 4000 fmol 
dose (open arrow) reveal significant between-group differences. An ANOVA produced an F3j3 =36.2; P<0.001. Post-hoc 
Bonferroni comparisons between groups at the 4000 fmol dose indicate: PBS vs Yl, no significant difference; PBS vs NPY, 
P<0.001; PBS vs Y2, P<0.001; Yl vs NPY, P<0.001; Yl vs Y2, P<0.001; NPY vs Y2, no significant difference. Results are 
similar for the 4 fmol comparison (filled arrow). Here, an ANOVA produced an F3.u = 12.13; P<0.001. Post-hoc 
Bonferroni comparisons for 4 fmol yield: PBS vs Yl, no significant difference; PBS vs NPY, P<0.05; PBS vs Y2, P<0.01; 
Yl vs NPY, P<0.05; Yl vs Y2, P<0.01; NPY vs Y2, no significant difference. Numbers on graph indicate Nfor each 
experimental group. From Ref 48. 
  
  
tions of the Yl agonist (LeuSl, Pro34 NPY) produced no 
apparent reduction in the TRH-stimulated increase of antral 
motility. Although application of the full sequence of NPY to 
the DVC inhibited motility more than Yl agonist, the inhibition 
was not as potent as that produced by equal doses of PYY or Y2 
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typical effects of all four peptides on strain-gauge recordings of 
gastric motility (48). 
The results on motility are exactly reversed for the effects of 
NPY, Yl and Y2 analogs in the DVC on basal gastric motility: 
the Yl agonist and NPY strongly activated motility from the 
low, basal state, while the Y2 agonist produced no effect on 
the already low motility. Figure 3 shows the typical effects of 
these peptides on gastric motility when applied to the DVC 
under anesthesia. Obviously, the anesthetic state of the 
preparation may significantly alter the motility level of the rat, 
as well as bias the effects of centrally applied peptides. 
However, it has been observed recently that the intracisternal 
application of PYY in awake rats produces a dose-dependent 
inhibition of gastric motility which is vagally-mediated (Fig. 4) 
(49). 
•        Neurophysiological Studies 
The effects of Yl and Y2 agonists on the excitability of vagal 
efferent neurons in the DMN show that these neurons may be 
an important target of the direct effects of PYY and NPY. 
Extracellular recording from spontaneously active DMN 
neurons, both in vivo and in vitro, confirm that PYY and the 
Y2 agonist peptide exert a predominantly inhibitory effect 
on DMN neurons. The inhibitory PYY and Y2 agonist effects 
on DMN neurons recorded in vitro under high 
magnesium/low calcium conditions ("synaptic blockade") 
are additionally significant, because they suggest that PYY 
effects on the DMN are direct and not mediated by synaptic 
inputs from other neurons. In contrast, similar studies done 
with the Yl agonist reveal that its effects on DMN neurons is 
excitatory (Figs 5-8) (53).   
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Figure 3. Effects on basal gastric motility of NPY, Yl, or Y2 agonists microinjected into the dorsal vagal complex. Data are 
depicted as means, +/- standard error. * = Bonferroni comparison to PBS was significantly different at the P<0.01 level. Note 





Figure 4. Intracisternal PYY in the awake rat suppresses gastric transit; the effect is mediated by the vagus nerve. Effects on 
gastric transit of intracisternal injections of vehicle (PBS), 400fmol of PYY in PBS or the TRH agonist RX77368 (33 pmol). 
Vagotomy does not effect basal, i.e. vehicle injection, gastric emptying in this model, but does eliminate the inhibitory effects 
of PYY as well as the excitatory effects of the TRH analog known to act via vagal efferents (REF). Numbers on graph indicate 
Nfor each experimental group. ** = P<0.01, Dunnetts test. From Ref 49. 
  
PYY, Y2 AGONISTS AND GASTROINHIBITION; THE 
JLEAL BRAKE" 
• The exposure of the intestinal lumen to fatty acids elicits a 
powerful inhibition of gastric motility. This phenomenon has 
been termed the "ileal brake" and its mechanism has been under 
investigation since the 1920's. Kosaka and Lim (54, 55) 
established that this ileal brake mechanism was, at least in 
part, hormonal, and that putative hormonal mediators isolated 
from the intestine possessed significant gastro-in-hibitory 
properties. This general class of inhibitory mediators were 
termed "enterogastrones". Considerable evidence has been 
collected in support of PYY as the principal mediator of this 
ileal brake effect (4, 5, 17, 26, 27). It is released by ileal 
endocrine cells in response to luminal fatty acid stimulation 
(5,6). When administered into the circulation, PYY evokes a 
strong, vagally mediated inhibition of proximal digestive 
functions (5, 56). 
A dense concentration of PYY binding sites is located in the 
DVC; the site of vago-vagal reflex control circuitry 
responsible for the vagal modulation of proximal digestive 
tract functions. Recent investigations have revealed that the 
DVC does not have a significant vascular diffusion barrier (24-
26). Thus, peptides of the PP family have no difficulty gaining 
ac- 
cess to the extracellular spaces of the DVC. 
Our studies with low doses of PYY applied directly to the 
DVC support the concept that the "enterogastrone" effects of 
PYY are mediated through the vagal innervation of the stomach. 
That is, (0 over a dose range consistent with physiological levels 
(4, 17, 27), PYY produces a profound inhibition of vagally 
mediated gastric motility, (zz) gastroinhibitory effects of DVC 
PYY are duplicated by the Y2 agonist, and (in) 
neurophysiological studies (27) suggest that the PYY and Y2 
agonist-evoked vagal gastroinhibition may be produced by 
direct inhibition of gastric DMN neurons. 
CENTRAL VAGAL GASTROEXCITATORY ACTIONS 
OF PYY AND NPY;  ACTION AT THE Y1 RECEPTOR. 
• In spite of the strong evidence that PYY or its Y2 receptor 
analog are associated with a vagally mediated inhibition of 
gastric function, other evidence provided support for PYY and 
NPY as potential activators of gastric motility, also through a 
central vagal efferent mechanism (27, 28). In these studies, 
higher doses of PYY delivered to the DVC evoked a 
significant stimulation of gastric motility. Geoghegan et al 
(29) and Lee et al (30) showed that ventricular injections of 
relatively high doses of NPY yielded significant increases in 
  
Rogers and Hermann 





Biomed Rev 8, 1997 
 
    
   
 
 




Figure 7. In vitro recording from a DMN neuron in the brainstem slice: inhibitory effect of PYY. Rate histogram showing the 
effects of PYY (50 fmol) on the spontaneous firing behavior of a DMN neuron recorded in the in vitro brainstem slice 
preparation under synoptic blockade conditions, i.e. high Mg++/low Ca++ media (a). Ten, superimposed, spontaneous DMN 
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Figure 8. In vitro recording from a DMN neuron illustrating the inhibitory effects of the Y2 agonist PYY 13-36. Rate 
histogram showing the effects of Y2 agonist (50 fmol) on the spontaneous firing behavior of a DMN neuron recorded in 
synaptic blockade media (a). Ten superimposed spontaneous DMN action potentials of same cell as in panel A, showing 






















gastric motility, acid secretion and pancreatic secretion, all of 
which were vagally mediated. These investigators proposed 
that NPY was acting as part of a mechanism, which connects 
the onset of feeding behavior with the onset of the "cephalic 
phase" of digestion control. 
Considerable experimental evidence links NPY with the central 
control of feeding behaviour. NPY microinjected into the 
paraventricular nucleus of the hypothalamus, or other nearby 
diencephalic regions which participate in the control of feeding 
behaviour, strongly elicits eating. NPY is synthesized in 
hypothalamic nuclei and released under conditions known to 
increase feeding behaviour, i.e. growth, pregnancy, and starvation 
(12). Blockade of synthesis of NPY or its receptors reduces 
feeding behaviour (15, 57, 58). Furthermore, there are 
significant NPYergic inputs to the DVC region of the brain-
stem (11, 43). Given that NPY is strongly associated with the 
initiation of feeding behaviour, it seems reasonable to also 
expect descending NPYergic co-control of autonomic 
functions which augment digestion. However, in spite of the 
ideological arguments and experimental data in support of 
this mechanism (29, 30), there are a number of reports which 
suggest that the central application of NPY, like PYY, could 
also produce a reduction in gastric motility or secretion (33-
35). 
Y1 AND Y2 RECEPTORS IN THE DVC: 
RECIPROCAL CONTROL OF GASTRIC FUNCTION? 
• One possible explanation for the conflicting nature of the 
effects of these peptides on gastric function involves the action 
of NPY and PYY on Y1 versus Y2 receptors in the DVC (27, 48, 
49, 53). Perhaps these two receptor populations (Yl and Y2) 
are normally segregated by morphological and/or 
physiological mechanisms which break down under 
experimental circumstances. For example, much of the PYY 
released from the ileum is rapidly converted to a specific Y2 
agonist (PYY 3-36) by aubiquitous diaminopeptidase (DAP-IV) 
(57). Under physiological conditions, PYY released into the 
circulation would ordinarily not exist long as a combined Y1-
Y2 agonist, i.e. native PYY, thus eliminating any PYY cross- 
talk with Y1 and Y2 receptors. DAP-IV post-processing of 
peptide hormones and neurotransmitters within the central 
nervous system is now recognized as an important step in 
determining 
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Figure 9. Effects of Yl agonist on DMN activity recorded in the in vitro brainstem slice preparation. Rate histogram 
showing the effects of Yl agonist (50 fmol) on the spontaneous firing behavior of a DMN neurons recorded in synaptic 
blockade media (a). Ten, superimposed, spontaneous DMN action potentials of same cell as recorded in panel A, showing the 
unitary nature of the recording (b). 
  
Figure 10. Hypothetical model of the segregation of Yl and Y2 receptor effects on a DMN neut-on controlling excitatory cholinergic inputs to the 
digestive tract. Under normal physiological conditions, PYY released into the circulation is largely converted to a specific Y2 agonist by the action of 
DAP-IV. Activation of the Y2 receptor leads to inhibition of the DMN neuron, and a reduction in cholinergic excitation of the digestive tract. However, 
high doses of PYY injected experimentally onto the DMN neuron will also activate Yl receptors. The result can be paradoxical effects on cholinergic 
control of digestion, since PYY has a similar binding affinity for both Yl and Y2 receptors. NPY released onto Yl receptors activates the DMN neuron 
and increases cholinergic excitation of the digestive tract. This would be appropriate if NPYergic; pathways act together to augment digestion and 
feeding behaviour at the same time. As before, the experimental injection of NPY onto this neuron will activate both the Yl and Y2 receptors with 









specific peptide actions (59, 60). Further, Y2 receptors might 
exist in higher concentrations than Yl receptors in areas of 
the DVC that are more accessible to circulating peptides, 
increasing the probability that circulating PYY or its Y2 
analog would elicit a Y2-mediated suppression of vagal 
cholinergic influences on the digestive process (23, 42). 
Conversely, NPY may normally be released as a neuro-
transmitter exclusively onto Yl receptors within the DVC. In 
this case, NPY would typically elicit a vagally mediated 
increase in digestive functions as seen in our results (also see 
29, 30). In other words, NPY may not exist in high 
concentrations outside synapses at Yl sites, eliminating NPY 
interaction at Y2 receptors (Fig. 10). 
CONFOUNDS OF EXPERIMENTAL PEPTIDE APPLICATION 
• The conflicting experimental results obtained by 
different doses and routes of central administration of PYY 
and NPY may be explained by simultaneous peptide actions at 
Y1 and Y2 sites which, under normal physiological conditions, 
may never occur (7). For example, CNS injection of a large 
amount of PYY may saturate DAP-IV, thereby allowing a 
significant amount of native PYY to gain access to Yl recep 
tors. Further, since PYY is being injected directly onto DVC 
structures (as opposed to arrival through the circulation), the 
peptide may be artificially placed in regions at high concen 
trations where it is not normally found, i.e. in the vicinity of Yl 
receptors. Since PYY has a very similar affinity for Y1 and Y2 
receptors (13), under experimental conditions, the peptide 
may activate both receptors, leading to conflicting results. 
Proof of this speculative scheme requires the histoanatomical 
demonstration that Y1 and Y2 receptors are located on different 
components of the DVC. Neurophysiological studies of Yl 
and Y2 agonist action on identifiable components of DVC 
motility regulation circuits will also be required to establish 
the functional significance of any difference in Yl and Y2 
receptor distribution. Similar logic applies to the interpretation 
of central actions of NPY. Perhaps NPY is released primarily 
onto Y1 receptors as a neurotransmitter in the DVC. These Y1 
receptors may be located outside the region where PYY might 
gain access via the circulation. Under normal circumstances, 
NPY would activate digestive functions via action on vagal 
mechanisms. Under experimental conditions, however, 
microinjection of NPY into the DVC would place it in contact 
withboth Yl and Y2 receptors. As with PYY, NPY has a nearly 
equivalent affinity for both YlandY2 receptors. Thus, the 
results of an application of NPY to the DVC by microinjection 
could be dependent upon the prevailing experimental 
conditions, e.g. basal versus stimulated motility. Critical 
histoanatomical and neurophysiological studies will be 
required to support or refute this hypothetical model . 
CONCLUSION 
• The vagal gastroinhibitory effects of PYY and NPY may 
be mediated by the Y2 receptor while the gastroexcita-tory 
effects of these same peptides may be mediated by the Yl 
receptor. The ultimate effects of Y2 and Yl receptor activation 
are inhibition and excitation, respectively, of DMN neurons 
which are responsible for controlling the cholinergic 
excitation of gastric smooth muscle. These observations may 
help to resolve some of the conflicting results obtained with 
these peptides in studies of autonomic control of digestive 
function. 
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